VeriStrat predicts patient outcomes in cancer therapy; U.K. NHS could use Down syndrome blood test by 2017;

> Biodesix's VeriStrat biomarker test picked those patients most likely to have better outcomes when treated with gemcitabine or erlotinib. Press release

> U.K. NHS could be using a blood test for Down syndrome screening by 2017, avoiding up to 300 miscarriages a year. Article

> A mutation in a gene that metabolizes amino acids acts as a marker for autism and epilepsy that may be treatable through diet. Press release | Abstract | Article | Article

> SOX2 mutations can be linked with aggressive lung cancer Abstract | Press release

> Changes in methylation patterns on DNA tag prostate cancer. Press release | Abstract

> Around half of people have thyroid nodules, but most of these are harmless; an 8-gene assay could pick out those that are cancerous, avoiding unnecessary surgery. Press release | Paper

> Inform Genomics has completed enrollment for the first phase of development for its lead platform product OnPART. Press release

And Finally… Eco-friendly blood glucose monitor could make diabetes checking greener. Article

Suggested Articles

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.

The FDA launched a center of excellence to oversee digital health products such as smartphone apps, wearable devices and software-based treatments.